Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lewin

Showing results (311-320 of 331) with videos related to

Pageof 34
Sort By:
Neurology and Therapy|June 24, 2023
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEMMitzi J Williams, Lilyana Amezcua, Angel Chinea, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Journal of Autism and Developmental Disorders|February 10, 2025
Caregiver Satisfaction with Anxiety Treatment for Autistic Youth: A Mixed Methods ExaminationLesley A Norris, Jonathan C Rabner, Marika Marklin, et al.
Journal of Child and Family Studies|July 28, 2017
The Treatment of Anxiety in Autism Spectrum Disorder (TAASD) Study: Rationale, Design and MethodsConnor M Kerns, Jeffrey J Wood, Philip C Kendall, et al.
Advances in Therapy|June 11, 2024
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel FumarateMark Gudesblatt, Barbara Bumstead, Marijean Buhse, et al.
Neurology|April 15, 2018
A multicenter examination and strategic revisions of the Yale Global Tic Severity ScaleJoseph F McGuire, John Piacentini, Eric A Storch, et al.
Journal of Child and Adolescent Psychopharmacology|October 15, 2014
Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotypeTanya K Murphy, Priyal D Patel, Joseph F McGuire, et al.
Journal of Child and Adolescent Psychopharmacology|May 13, 2014
Utility of the diagnostic interview schedule for children for assessing Tourette syndrome in childrenAdam B Lewin, Jonathan W Mink, Rebecca H Bitsko, et al.
Evidence-Based Practice in Child and Adolescent Mental Health|June 16, 2023
Brief youth self-report screener for tics: Can a subscale of the Motor tic, Obsession and compulsion, and Vocal tic Evaluation Survey (MOVES) identify tic disorders in youth?Adam B Lewin, Tanya K Murphy, Jonathan W Mink, et al.
Journal of Child and Adolescent Psychopharmacology|December 4, 2019
Measuring Treatment Response in Pediatric Trichotillomania: A Meta-Analysis of Clinical TrialsLuis C Farhat, Emily Olfson, Jessica L S Levine, et al.
Pageof 34

Showing results (311-320 of 331) with videos related to

Sort By:
Pageof 34
Neurology and Therapy|June 24, 2023
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEMMitzi J Williams, Lilyana Amezcua, Angel Chinea, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Journal of Autism and Developmental Disorders|February 10, 2025
Caregiver Satisfaction with Anxiety Treatment for Autistic Youth: A Mixed Methods ExaminationLesley A Norris, Jonathan C Rabner, Marika Marklin, et al.
Journal of Child and Family Studies|July 28, 2017
The Treatment of Anxiety in Autism Spectrum Disorder (TAASD) Study: Rationale, Design and MethodsConnor M Kerns, Jeffrey J Wood, Philip C Kendall, et al.
Advances in Therapy|June 11, 2024
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel FumarateMark Gudesblatt, Barbara Bumstead, Marijean Buhse, et al.
Neurology|April 15, 2018
A multicenter examination and strategic revisions of the Yale Global Tic Severity ScaleJoseph F McGuire, John Piacentini, Eric A Storch, et al.
Journal of Child and Adolescent Psychopharmacology|October 15, 2014
Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotypeTanya K Murphy, Priyal D Patel, Joseph F McGuire, et al.
Journal of Child and Adolescent Psychopharmacology|May 13, 2014
Utility of the diagnostic interview schedule for children for assessing Tourette syndrome in childrenAdam B Lewin, Jonathan W Mink, Rebecca H Bitsko, et al.
Evidence-Based Practice in Child and Adolescent Mental Health|June 16, 2023
Brief youth self-report screener for tics: Can a subscale of the Motor tic, Obsession and compulsion, and Vocal tic Evaluation Survey (MOVES) identify tic disorders in youth?Adam B Lewin, Tanya K Murphy, Jonathan W Mink, et al.
Journal of Child and Adolescent Psychopharmacology|December 4, 2019
Measuring Treatment Response in Pediatric Trichotillomania: A Meta-Analysis of Clinical TrialsLuis C Farhat, Emily Olfson, Jessica L S Levine, et al.
Pageof 34